## Chong Sun

## List of Publications by Year

 in descending orderSource: https:/|exaly.com/author-pdf/1920400/publications.pdf
Version: 2024-02-01


| 1 | Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483, 100-103. | 27.8 | 1,769 |
| :---: | :---: | :---: | :---: |
| 2 | Regulation and Function of the PD-L1 Checkpoint. Immunity, 2018, 48, 434-452. | 14.3 | 1,437 |
| 3 | Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 2014, 508, 118-122. | 27.8 | 702 |
| 4 | Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature, 2017, 549, 106-110. | 27.8 | 501 |
| 5 | MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-î2 Receptor Signaling. Cell, 2012, 151, 937-950. | 28.9 | 371 |
| 6 | Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. Cell Reports, 2014, 7, 86-93. | 6.4 | 266 |
| 7 | Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. Nature Biotechnology, 2011, 29, 542-546. | 17.5 | 207 |
| 8 | EGFR activation limits the response of liver cancer to lenvatinib. Nature, 2021, 595, 730-734. | 27.8 | 183 |
| 9 | Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends in Biochemical Sciences, 2014, 39, 465-474. | 7.5 | 134 |
| 10 | RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells. Cell Reports, 2014, 8, 1475-1483. | 6.4 | 103 |
| 11 | BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. Cell Reports, 2016, 16, 263-277. | 6.4 | 61 |
| 12 | SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. Cell Research, 2015, 25, 445-458. | 12.0 | 36 |
| 13 | Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant. Npj Breast Cancer, 2022, 8, . | 5.2 | 1 |

